In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent

European Journal of Pharmacology

Volumn 779, Issue , 2016, Pages 138-146

  Zhang, Quanwei ^a   Lin, Zhexuan ^a   Yin, Xiukai ^a   Tang, Lingzhi ^a   Luo, Hongjun ^a   Li, Hui ^a   Zhang, Yuan ^a   Luo, Wenhong ^a  

^a SHANTOU UNIVERSITY   (China)

Author keywords

Anti angiogenesis; bFGF; Hepatocellular carcinoma; Hydralazine; VEGF

Indexed keywords

CISPLATIN; FIBROBLAST GROWTH FACTOR 2; HYDRALAZINE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; ARTICLE; CAPILLARY DENSITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING; ANIMAL; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEP-G2 CELL LINE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; HYDRALAZINE; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84961167044     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.03.021     Document Type: Article

References (60)

1. I. Arnaoutova, J. George, H.K. Kleinman, and G. Benton The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art Angiogenesis 12 2009 267 274
2. W. Auerbach, and R. Auerbach Angiogenesis inhibition: a review Pharmacol. Ther. 63 1994 265 311
3. S.V. Bhadada, B.R. Goyal, and M.M. Patel Angiogenic targets for potential disorders Fundam. Clin. Pharmacol. 25 2011 29 47
4. S. Brem Angiogenesis and cancer control: from concept to therapeutic trial Cancer Control 6 1999 436 458
5. Q.Z. Cao, and Z.B. Lin Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell Life Sci. 78 2006 1457 1463
6. S. Carbajo-Pescador, R. Ordonez, M. Benet, R. Jover, A. Garcia-Palomo, J.L. Mauriz, and J. Gonzalez-Gallego Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells Br. J. Cancer 109 2013 83 91
7. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat. Med. 6 2000 389 395
8. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
9. Y.W. Chen, and G.C.Y. Chiou Antioxidant effect of hydralazine on retinal pigment cells and its potential use in the therapy of age-related macular degeneration Int. J. Ophthalmol. 8 2008 19 24
10. A.L. Cheng, Y.C. Shen, and A.X. Zhu Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma Oncology 81 2011 372 380
11. L. Coultas, K. Chawengsaksophak, and J. Rossant Endothelial cells and VEGF in vascular development Nature 438 2005 937 945
12. M.J. Cross, and L. Claesson-Welsh FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition Trends Pharmacol. Sci. 22 2001 201 207
13. B.B. da Silva, P.V. Lopes-Costa, A.R. dos Santos, E.C. de Sousa-Junior, A.P. Alencar, C.G. Pires, and M.A. Rosal Comparison of three vascular endothelial markers in the evaluation of Microvessel density in breast cancer Eur. J. Gynaecol. Oncol. 30 2009 285 288
14. P.M. Das, and R. Singal DNA methylation and cancer J. Clin. Oncol. 22 2004 4632 4642
15. J.H. Distler, A. Hirth, M. Kurowska-Stolarska, R.E. Gay, S. Gay, and O. Distler Angiogenic angiostatic factors molecular control angiogenesis Q. J. Nucl. Med. 47 2003 149 161
16. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
17. J. Folkman Fundamental concepts of the angiogenic process Curr. Mol. Med. 3 2003 643 651
18. J. Folkman Angiogenesis Annu. Rev. Med. 57 2006 1 18
19. J. Folkman Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action Exp. Cell Res. 312 2006 594 607
20. J. Folkman, and M. Klagsbrun Angiogenic factors Science 235 1987 442 447
21. J. Folkman, E. Merler, C. Abernathy, and G. Williams Isolation of a tumor factor responsible for angiogenesis J. Exp. Med. 133 1971 275 288
22. P. Gerwins, E. Skoldenberg, and L. Claesson-Welsh Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis Crit. Rev. Oncol. Hematol. 34 2000 185 194
23. R.S. Go, and W.G. Owen The rat aortic ring assay for in vitro study of angiogenesis Methods Mol. Med. 85 2003 59 64
24. M.R. Horsman, A.B. Bohn, and M. Busk Vascular targeting therapy: potential benefit depends on tumor and host related effects Exp. Oncol. 32 2010 143 148
25. R.K. Jain Molecular regulation of vessel maturation Nat. Med. 9 2003 685 693
26. G.R. Jones, M.J. Frohn, and A.H. Beckett Liminal therapy: a strategy for the complete and selective destruction of malignant tissue in situ Med. Hypotheses 15 1984 349 359
27. L. Lamalice, F. Le Boeuf, and J. Huot Endothelial cell migration during angiogenesis Circ. Res. 100 2007 782 794
28. A. Li, M.L. Varney, J. Valasek, M. Godfrey, B.J. Dave, and R.K. Singh Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis Angiogenesis 8 2005 63 71
29. R. Li, H. Li, H.J. Luo, Z.X. Lin, Z.W. Jiang, and W.H. Luo SSAO inhibitors suppress Hepatocellular tumor growth in mice Cell Immunol. 283 2013 61 69
30. J. Marshall Transwell((R)) invasion assays Methods Mol. Biol. 769 2011 97 110
31. D.B. Mendel, R.E. Schreck, D.C. West, G. Li, L.M. Strawn, S.S. Tanciongco, S. Vasile, L.K. Shawver, and J.M. Cherrington The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function Clin. Cancer Res. 6 2000 4848 4858
32. M. Mise, S. Arii, H. Higashituji, M. Furutani, M. Niwano, T. Harada, S. Ishigami, Y. Toda, H. Nakayama, M. Fukumoto, J. Fujita, and M. Imamura Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor Hepatology 23 1996 455 464
33. J. Muto, K. Shirabe, K. Sugimachi, and Y. Maehara Review of angiogenesis in hepatocellular carcinoma Hepatol. Res. 45 2015 1 9
34. M. Nguyen, H. Watanabe, A.E. Budson, J.P. Richie, and J. Folkman Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients J. Natl. Cancer Inst. 85 1993 241 242
35. J. Patrick, M.D. Loehrer, H. Lawrence, and M.D. Einhorn Cisplatin Ann. Intern. Med. 100 1984 704 713
36. D. Ribatti, and A. Vacca Models for studying angiogenesis in vivo Int. J. Biol. Markers 14 1999 207 213
37. D. Ribatti, A. Vacca, L. Roncali, and F. Dammacco The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis Int. J. Dev. Biol. 40 1996 1189 1197
38. D. Ribatti, A. Vacca, L. Roncali, and F. Dammacco The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis Curr. Pharm. Biotechnol. 1 2000 73 82
39. W. Risau Mechanisms of angiogenesis Nature 386 1997 671 674
40. L.G. Rodriguez, X. Wu, and J.L. Guan Wound-healing assay Methods Mol. Biol. 294 2005 23 29
41. Y. Safdari, M. Khalili, M.A. Ebrahimzadeh, Y. Yazdani, and S. Farajnia Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action Pharmacol. Res. 93 2015 1 10
42. B. Segura-Pacheco, E. Perez-Cardenas, L. Taja-Chayeb, A. Chavez-Blanco, A. Revilla-Vazquez, L. Benitez-Bribiesca, and A. Duenas-Gonzalez Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine J. Transl. Med. 4 2006 32
43. D.M. Sherer, and O. Abulafia Angiogenesis during implantation, and placental and early embryonic development Placenta 22 2001 1 13
44. M.R. Shin, S.K. Kang, Y.S. Kim, S.Y. Lee, S.C. Hong, and E.C. Kim TNF-alpha and LPS activate angiogenesis Via VEGF and SIRT1 signalling in human dental pulp cells Int. Endod. J. 48 2015 705 716
45. D.W. Siemann, M.C. Bibby, G.G. Dark, A.P. Dicker, F.A. Eskens, M.R. Horsman, D. Marme, and P.M. Lorusso Differentiation and definition of vascular-targeted therapies Clin. Cancer Res. 11 2005 416 420
46. D.W. Siemann, and M.R. Horsman Vascular targeted therapies in oncology Cell. Tissue Res. 335 2009 241 248
47. Y. Song, and C. Zhang Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression Cancer Chemother. Pharmacol. 63 2009 605 613
48. H.C. Sun, and Z.Y. Tang Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives J. Cancer Res. Clin. Oncol. 130 2004 307 319
49. M. Vicente-Manzanares, X. Ma, R.S. Adelstein, and A.R. Horwitz Non-muscle myosin II Takes centre stage in cell adhesion and migration Nat. Rev. Mol. Cell Biol. 10 2009 778 790
50. N. Weidner, J.P. Semple, W.R. Welch, and J. Folkman Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma N. Engl. J. Med. 324 1991 1 8
51. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat. Med. 17 2011 1359 1370
52. J. Wilting, B. Christ, and M. Bokeloh A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors. Studies on the effects of carriers, PBS, Angiogenin, and bFGF Anat. Embryol. 183 1991 259 271
53. L. Yadav, N. Puri, V. Rastogi, P. Satpute, and V. Sharma Tumour angiogenesis angiogenic inhibitors: a review J. Clin. Diagn. Res. 9 2015 XE01 XE05
54. F. Yang, J. Li, J. Zhu, D. Wang, S. Chen, and X. Bai Hydroxysafflor yellow a inhibits angiogenesis of hepatocellular carcinoma Via blocking ERK/MAPK and NF-kappaB signaling pathway in H22 tumor-bearing mice Eur. J. Pharmacol. 754 2015 105 114
55. J. Yang, X. Li, Y. Xue, N. Wang, and W. Liu Anti-hepatoma activity and mechanism of corn silk polysaccharides in H22 tumor-bearing mice Int. J. Biol. Macromol. 64 2014 276 280
56. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 2003 427 434
57. T. Yi, S.G. Cho, Z. Yi, X. Pang, M. Rodriguez, Y. Wang, G. Sethi, B.B. Aggarwal, and M. Liu Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways Mol. Cancer Ther. 7 2008 1789 1796
58. P. Zambrano, B. Segura-Pacheco, E. Perez-Cardenas, L. Cetina, A. Revilla-Vazquez, L. Taja-Chayeb, A. Chavez-Blanco, E. Angeles, G. Cabrera, K. Sandoval, C. Trejo-Becerril, J. Chanona-Vilchis, and A. Duenas-Gonzalez A phase I study of Hydralazine to demethylate and reactivate the expression of tumor suppressor genes BMC Cancer 5 2005 44
59. A.X. Zhu Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann. Surg. Oncol. 17 2010 1247 1256
60. A.X. Zhu, D.G. Duda, D.V. Sahani, and R.K. Jain HCC and angiogenesis: possible targets and future directions Nat. Rev. Clin. Oncol. 8 2011 292 301